Relay Therapeutics (RLAY) Projected to Post Quarterly Earnings on Wednesday

Relay Therapeutics (NASDAQ:RLAY) is projected to announce its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect the company to announce earnings of ($0.41) per share and revenue of $0.16 million for the quarter. Individuals can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Friday, November 7, 2025 at 4:00 PM ET.

Relay Therapeutics (NASDAQ:RLAY) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.08. The company had revenue of $0.70 million for the quarter, compared to analyst estimates of $0.07 million. On average, analysts expect Relay Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Relay Therapeutics Price Performance

NASDAQ RLAY opened at $7.52 on Wednesday. The company has a market cap of $1.30 billion, a price-to-earnings ratio of -3.86 and a beta of 1.75. The stock’s fifty day moving average price is $5.02 and its 200 day moving average price is $3.88. Relay Therapeutics has a 1 year low of $1.77 and a 1 year high of $7.60.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Captrust Financial Advisors acquired a new stake in shares of Relay Therapeutics in the second quarter valued at about $49,000. Cerity Partners LLC purchased a new stake in Relay Therapeutics during the 2nd quarter valued at about $51,000. Jump Financial LLC purchased a new stake in Relay Therapeutics during the 2nd quarter valued at about $53,000. Dynamic Technology Lab Private Ltd acquired a new stake in Relay Therapeutics in the 1st quarter valued at about $53,000. Finally, Sei Investments Co. purchased a new position in Relay Therapeutics in the 2nd quarter worth approximately $89,000. 96.98% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. HC Wainwright cut their price target on shares of Relay Therapeutics from $16.00 to $14.00 and set a “buy” rating on the stock in a report on Tuesday, August 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Relay Therapeutics in a research note on Tuesday, October 14th. Raymond James Financial reduced their target price on shares of Relay Therapeutics from $29.00 to $19.00 and set a “strong-buy” rating for the company in a report on Friday, August 8th. Finally, Guggenheim assumed coverage on shares of Relay Therapeutics in a report on Thursday, September 4th. They issued a “buy” rating and a $15.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $16.50.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.